These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 4771851)

  • 21. [A new contrast media for excretion urography].
    Heynen U
    Landarzt; 1968 Sep; 44(27):Suppl:10-3. PubMed ID: 4883451
    [No Abstract]   [Full Text] [Related]  

  • 22. [Use of a new water-soluble contrast medium, iodamide 300, in urography and cerebral angiography].
    Corsi M; Tassini T
    Quad Radiol; 1969; 34(3):187-206. PubMed ID: 5362794
    [No Abstract]   [Full Text] [Related]  

  • 23. Urography with non-ionic contrast media: I. Diagnostic quality and tolerance of iohexol in comparison with meglumine amidotrizoate.
    Taenzer V; Heep H; Clauss W
    Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd; 1983; 118():148-52. PubMed ID: 6139070
    [No Abstract]   [Full Text] [Related]  

  • 24. [Side reactions and complications in intravenous urography].
    Shatov AV
    Vestn Rentgenol Radiol; 1987; (4):59-62. PubMed ID: 3672886
    [No Abstract]   [Full Text] [Related]  

  • 25. The bolus effect in excretory urography.
    Dure-Smith P; Simenhoff M; Zimskind PD; Kodroff M
    Radiology; 1971 Oct; 101(1):29-34. PubMed ID: 5111977
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparative study of the methylglucamine salts of iodamide and iothalamate in clinical urography.
    Owen JP; Keir MJ; Nair KV; Lauckner D; Wilsdon JB
    Clin Radiol; 1981 May; 32(3):341-6. PubMed ID: 7237916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Practical use of a new hydrosoluble tri-iodide opacifying agent (A.G. 58-107) in intravenous urography].
    Chevrot L; Chevrot A; Dor P; Kandelman M; Epineau R
    J Radiol Electrol Med Nucl; 1970 May; 51(5):306-7. PubMed ID: 5502374
    [No Abstract]   [Full Text] [Related]  

  • 28. Urography with non-ionic contrast media: II. Diagnostic quality and tolerance of iopromide in comparison with ioxaglate.
    Taenzer V; Meiisel P; Hartwig P
    Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd; 1983; 118():153-5. PubMed ID: 6139071
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparative study of the sodium salts of iodamide and iothalamate in clinical urography.
    Owen JP; Keir MJ; Lamballe AK; Laker MF; Fitzjohn TP; Wilsdon JB; Murray A; Campbell RW
    Clin Radiol; 1983 May; 34(3):353-7. PubMed ID: 6839661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of iopromide in rat and dog.
    Mützel W; Speck U; Weinmann HJ
    Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd; 1983; 118():85-90. PubMed ID: 6139085
    [No Abstract]   [Full Text] [Related]  

  • 31. [Intravenous pyelography in children comparative study: ioxitalamates - ioxaglates (author's transl)].
    Montagne JP; Fauré C
    Ann Radiol (Paris); 1982 Mar; 25(3):210-2. PubMed ID: 7092111
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmacokinetics of iodamide in normal subjects and in patients with renal impairment.
    Difazio LT; Singhvi SM; Heald AF; McKinstry DN; Brosman SA; Gillenwater JY; Willard DA
    J Clin Pharmacol; 1978 Jan; 18(1):35-41. PubMed ID: 338644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Theoretical approach to the optimum exposure time in intravenous pyelography].
    Ueno A
    Nihon Jinzo Gakkai Shi; 1984 Aug; 26(8):1007-15. PubMed ID: 6513172
    [No Abstract]   [Full Text] [Related]  

  • 34. [Intravenous cholegraphy with biligram. Clinical pharmacology].
    Taenzer V; Herms HJ
    Fortschr Geb Rontgenstr Nuklearmed; 1971 Jan; 114(1):102-7. PubMed ID: 5099735
    [No Abstract]   [Full Text] [Related]  

  • 35. [Clinical experience with iodamide meglumine (Conraxin-L) used in cerebral angiography--evaluation of contrast and viscosity].
    Fukushima T; Manaka S; Hirakawa K; Mogami T
    Rinsho Hoshasen; 1972 Sep; 17(9):636-40. PubMed ID: 4675595
    [No Abstract]   [Full Text] [Related]  

  • 36. [Distribution and excretion of iodamide-380 determined by roentgen fluorescence analysis].
    Zajcik VE; Amosov IS; Frolova EI; Jakovlev VJa
    Radiol Diagn (Berl); 1983; 24(3):429-34. PubMed ID: 6611913
    [No Abstract]   [Full Text] [Related]  

  • 37. [Comparison of the side effects of urographic contrast media (iothalamate, diatrizoate, iodamide, iopamidol) within the scope of a CT study].
    Stellamor K; Hruby W; Assinger S; Luckner H
    Radiologe; 1984 Oct; 24(10):488-90. PubMed ID: 6505221
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Iodamide-300 and 380: evaluation of the results of clinical trials in angiography and urography].
    Absava GI; Rabkin IKh; Rozenshtraukh LS; Krivenko EV
    Vestn Rentgenol Radiol; 1986; (1):74-7. PubMed ID: 3518227
    [No Abstract]   [Full Text] [Related]  

  • 39. Acute and late adverse reactions to low-osmolal contrast media.
    Mikkonen R; Kontkanen T; Kivisaari L
    Acta Radiol; 1995 Jan; 36(1):72-6. PubMed ID: 7833173
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Preliminary clinical studies with a new non-ionic contrast medium (Iopamidol) in intravenous pyelography].
    Miyakawa M; Yoshida O
    Hinyokika Kiyo; 1984 Mar; 30(3):431-5. PubMed ID: 6380240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.